ArticleLasers in medical science2026
Blue laser inferior turbinate reduction for medically refractory chronic rhinitis: a retrospective analysis of clinical outcomes and optimal energy settings.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blue-Laser Posterior Nasal Neurolysis via Dual Layer Nerve Modulation for Chronic Rhinitis.Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aims to evaluate the clinical efficacy of 445 nm blue laser inferior turbinate reduction (BITR) and establish optimal energy parameters for patients with chronic rhinitis (CR) refractory to pharmacotherapy. This was a retrospective cohort study of adult patients with medically refractory CR, a Nasal Obstruction Symptom Evaluation (NOSE) score ≥ 6, and a nasal congestion score ≥ 2. Turbinate hypertrophy was graded using the Camacho classification. Patients were stratified into Group A (Grade 3) and Group B (Grade 4). Primary endpoints were changes in NOSE scores and 12-hour Reflective Total Nasal Symptom Score (12-h rTNSS) at 1, 3, and 6 months. At 6 months, laser energy settings were analyzed in the top 50% of responders to determine optimal settings. Eighty-four patients were analyzed. At 6 months, NOSE scores improved by a mean of 91.1% in Group A and 88.0% in Group B (p < 0.001 for both). At 3 months, the 12-h rTNSS improved by 58.2% and 54.9%, respectively (p < 0.001 for both). In the top 50% of responders, the optimal mean energy delivered was 219 J (anterior) and 51 J (middle) for Group A, and 332 J (anterior) and 60 J (middle) for Group B. Postoperative complications were minimal. BITR is a safe and effective office-based procedure for medically refractory CR. To optimize outcomes, we recommend energy settings of approximately 219 J (anterior) and 51 J (middle) for moderate hypertrophy, and 332 J (anterior) and 60 J (middle) for severe hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.